While treatment with statins still represents the most important therapeutical approach for the treatment of hypercholesterolemia, more recently, PCSK9 (proprotein convertase subtilisin/kexin Type 9) inhibitors, are being prescribed in “high risk” and “very high risk” patients, due to their effectiveness in reducing LDL-C (low density lipoprotein cholesterol) by over 60% (2, 3). This evidence concerns the gene PCSK9 and familial hypercholesterolemia.